Martin R J, Wanger J S, Irvin C G, Bucher Bartelson B, Cherniack R M
National Jewish Center for Immunology and Respiratory Medicine, Denver, CO 80206, USA.
Chest. 1997 Jul;112(1):53-6. doi: 10.1378/chest.112.1.53.
The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 < 60% predicted was acceptable.
Retrospective analysis of challenges in 88 patients with a baseline FEV1 of < 60% predicted (mean=45.8%; range, 22 to 59%.
Academic institutions.
There were only four individuals whose FEV1 did not return to > 90% of baseline following one poststudy beta2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome.
In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.
启动乙酰甲胆碱支气管高反应性测试的基线值下限尚未明确确立。建议范围从大于1升至预测值的80%以上。目的是确定预测第一秒用力呼气容积（FEV1）<60%是否可接受。
对88例基线FEV1<预测值60%（平均=45.8%；范围22%至59%）患者的激发试验进行回顾性分析。
学术机构。
仅4例患者在研究后接受一次β2受体激动剂治疗后FEV1未恢复至基线的>90%。所有4例对第二次治疗有反应。任何个体在激发试验后均无不良后遗症。年龄（最高79岁）和性别均不影响结果。
在慢性中度至重度哮喘中，即使是基线FEV1较低的患者，似乎也可安全地进行支气管高反应性测试。
